Disease foundations are advocates, funders, partners
This article was originally published in Scrip
Companies with preclinical compounds might not think of institutions with limited resources as a first choice for early stage funding, but during a time when financing is hard to come by, disease foundations may be realistic drug development partners.
You may also be interested in...
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Amgen’s R&D programs are vitally important as sales of multiple blockbusters continue to drop, but one major late-stage asset had disappointing results and another key drug has an aggressive competitor.
The company has assembled small molecule discovery capabilities for the development of targeted cancer drugs that it believes rivals big pharma efforts and will fulfill patients’ unmet needs.